Rapid Growth GenBody America is rapidly expanding its US footprint with a new manufacturing facility and planned headcount growth in regulatory, product development, and sales, signaling increased demand for diagnostic manufacturing capacity and regional support.

US Manufacturing The new US factory in California aims to produce SARS-CoV-2 rapid tests under NIH contracts, presenting opportunities to position GenBody as a domestically supported supplier for US healthcare systems and distributors seeking faster delivery and local compliance.

Diverse Diagnostics GenBody’s in-house monoclonal antibodies and recombinant antigens across 78 diseases create cross-sell potential for broader diagnostic panels, enabling partnerships with clinical laboratories and point-of-care networks seeking expanded test portfolios.

Regulatory Push FDA EUA experience for COVID-19 rapid tests and ongoing regulatory staffing suggests a need for regulatory consulting, quality systems, and post-market surveillance services to accelerate market access for new products.

US Expansion The company’s aggressive hiring and regional presence in Southern California indicate warm outreach opportunities with local hospitals, clinics, and distributors for contract manufacturing, private-label tests, and service/support contracts.